Berenberg Bank set a €74.80 ($86.98) price objective on Fresenius SE & Co KGaA (FRA:FRE) in a research report released on Monday, Borsen Zeitung reports. The firm currently has a buy rating on the stock.

FRE has been the topic of a number of other reports. Jefferies Financial Group set a €53.00 ($61.63) price objective on Fresenius SE & Co KGaA and gave the company a neutral rating in a research note on Thursday, May 2nd. Morgan Stanley set a €50.00 ($58.14) target price on Fresenius SE & Co KGaA and gave the company a neutral rating in a report on Wednesday, May 22nd. Warburg Research set a €65.00 ($75.58) target price on Fresenius SE & Co KGaA and gave the company a buy rating in a report on Friday, July 26th. Barclays set a €52.00 ($60.47) target price on Fresenius SE & Co KGaA and gave the company a neutral rating in a report on Thursday, July 18th. Finally, Independent Research set a €51.00 ($59.30) target price on Fresenius SE & Co KGaA and gave the company a neutral rating in a report on Friday, August 2nd. Nine research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. The stock has an average rating of Buy and a consensus target price of €58.80 ($68.37).

Shares of Fresenius SE & Co KGaA stock opened at €41.75 ($48.55) on Monday. Fresenius SE & Co KGaA has a 52-week low of €60.16 ($69.95) and a 52-week high of €80.00 ($93.02). The stock’s 50-day simple moving average is €45.46 and its 200 day simple moving average is €47.66.

About Fresenius SE & Co KGaA

Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.

Featured Article: The Structure of a Futures Contract

Analyst Recommendations for Fresenius SE & Co KGaA (FRA:FRE)

Receive News & Ratings for Fresenius SE & Co KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co KGaA and related companies with MarketBeat.com's FREE daily email newsletter.